Reuters logo
BRIEF-Cellectis submits IND application for UCART123
January 3, 2017 / 10:45 PM / 10 months ago

BRIEF-Cellectis submits IND application for UCART123

Jan 4 (Reuters) - Cellectis Sa

* Cellectis submits IND application for UCART123, an allogeneic gene edited car t-cell product candidate, in AML and BPDCN

* Cellectis sa says pending regulatory clearance, plans to initiate phase 1 clinical trials in first half of 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below